Literature DB >> 26998032

Plasma levels of D-dimer in a 5-year-old girl with systemic juvenile idiopathic arthritis: A case report and literature review.

Qiang Xu1, Chang-Song Lin1.   

Abstract

The present study reported high levels of D-dimer associated with multiple joint pain in a 5-year-old patient with systemic juvenile idiopathic arthritis (JIA). While treatment with methotrexate (MTX), hydroxychloroquine and methylprednisolone was found to reduce the D-dimer level and alleviated joint pain, the fever was not effectively controlled. Addition of etanercept to the treatment regimen from week 2 resulted in a clinical remission. Following 4-6 months of therapy, the D-dimer level of the patient returned to the normal range, and symptoms of noticeable joint pain and fever were absent. A literature search showed that the levels of D-dimer may be associated with JIA disease severity, and can serve as a prognostic biomarker for JIA treatment. In conclusion, the present study demonstrated that, while MTX therapy effectively reduced D-dimer levels, addition of etanercept to the treatment regimen was required to achieve a long-lasting remission of clinical symptoms, including fever.

Entities:  

Keywords:  D-dimer; etanercept; juvenile idiopathic arthritis

Year:  2016        PMID: 26998032      PMCID: PMC4774404          DOI: 10.3892/etm.2016.3009

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  19 in total

1.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

2.  Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis?

Authors:  Alberto Martini
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

Review 3.  Diagnosis and management of juvenile idiopathic arthritis.

Authors:  Femke H M Prince; Marieke H Otten; Lisette W A van Suijlekom-Smit
Journal:  BMJ       Date:  2010-12-03

Review 4.  Systemic onset juvenile rheumatoid arthritis.

Authors:  R Schneider; R M Laxer
Journal:  Baillieres Clin Rheumatol       Date:  1998-05

5.  Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

Authors:  Pierre Quartier; Pierre Taupin; Franck Bourdeaut; Irène Lemelle; Pascal Pillet; Michel Bost; Jean Sibilia; Isabelle Koné-Paut; Sylvie Gandon-Laloum; Marc LeBideau; Brigitte Bader-Meunier; Richard Mouy; Marianne Debré; Paul Landais; Anne-Marie Prieur
Journal:  Arthritis Rheum       Date:  2003-04

Review 6.  Juvenile idiopathic arthritis.

Authors:  Berent Prakken; Salvatore Albani; Alberto Martini
Journal:  Lancet       Date:  2011-06-18       Impact factor: 79.321

7.  Soluble intercellular adhesion molecule-1 and E-selectin as markers of disease activity and endothelial activation in juvenile idiopathic arthritis.

Authors:  Bradley J Bloom; Sarah M Nelson; Daniel Eisenberg; Anthony J Alario
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

8.  Persistent elevation of fibrin D-dimer predicts longterm outcome in systemic juvenile idiopathic arthritis.

Authors:  Bradley J Bloom; Anthony J Alario; Laurie C Miller
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

Review 9.  Juvenile rheumatoid arthritis: outcome and treatment for the 1990s.

Authors:  C A Wallace; J E Levinson
Journal:  Rheum Dis Clin North Am       Date:  1991-11       Impact factor: 2.670

10.  Soluble adhesion molecules ICAM-1 and E-selectin in juvenile arthritis: clinical and laboratory correlations.

Authors:  P Dolezalová; P Telekesová; D Nemcová; J Hoza
Journal:  Clin Exp Rheumatol       Date:  2002 Mar-Apr       Impact factor: 4.473

View more
  1 in total

1.  Elevated Serum D-Dimer May Reflect the Presence of Gut Inflammation in Spondyloarthritis.

Authors:  Jiaqi Feng; Jia Li; Yixuan Li; Yuyang Jin; Fang Du; Xiaoxiang Chen
Journal:  Front Med (Lausanne)       Date:  2022-01-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.